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Abstract
Background: The rate of decline of antibody titers to influenza following infection can affect results of serological
surveys, and may explain re-infection and recurrent epidemics by the same strain.
Methods: We followed up a cohort who seroconverted on hemagglutination inhibition (HI) antibody titers (≥4-fold
increase) to pandemic influenza A(H1N1)pdm09 during a seroincidence study in 2009. Along with the pre-epidemic
sample, and the sample from 2009 with the highest HI titer between August and October 2009 (A), two additional
blood samples obtained in April 2010 and September 2010 (B and C) were assayed for antibodies to A(H1N1)
pdm09 by both HI and virus microneutralization (MN) assays. We analyzed pair-wise mean-fold change in titers and
the proportion with HI titers ≥ 40 and MN ≥ 160 (which correlated with a HI titer of 40 in our assays) at the 3
time-points following seroconversion.
Results: A total of 67 participants contributed 3 samples each. From the highest HI titer in 2009 to the last sample
in 2010, 2 participants showed increase in titers (by HI and MN), while 63 (94%) and 49 (73%) had reduction in HI
and MN titers, respectively. Titers by both assays decreased significantly; while 70.8% and 72.3% of subjects had
titers of ≥ 40 and ≥ 160 by HI and MN in 2009, these percentages decreased to 13.9% and 36.9% by September
2010. In 6 participants aged 55 years and older, the decrease was significantly greater than in those aged below 55,
so that none of the elderly had HI titers ≥ 40 nor MN titers ≥ 160 by the final sample. Due to this decline in titers,
only 23 (35%) of the 65 participants who seroconverted on HI in sample A were found to seroconvert between the
pre-epidemic sample and sample C, compared to 53 (90%) of the 59 who seroconverted on MN on Sample A.
Conclusions: We observed marked reduction in titers 1 year after seroconversion by HI, and to a lesser extent by
MN. Our findings have implications for re-infections, recurrent epidemics, vaccination strategies, and for cohort
studies measuring infection rates by seroconversion.
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Background
Recurrent epidemics of influenza occur in winter in tem-
perate climates, whereas in Singapore and other tropical
areas, influenza activity is observed all year round with
less predictable peaks of activity [1,2]. Following the emer-
gence of pandemic influenza A(H1N1)pdm09 in March
2009, it was estimated that between 17–31% of partici-
pants in a multi-country study were seropositive after the
initial epidemic of infections [3]. Despite this, multiple ep-
idemics of infection with the same virus subsequently oc-
curred in Singapore and elsewhere in late 2009 and 2010
[4,5], with some evidence of shifts in age distribution to
involve older individuals [6,7].
The ability of influenza virus to undergo antigenic drift
by its frequent mutations allows it to cause re-infections
of the same individual, and also provides one explan-
ation for recurrent epidemics from different strains of
the same influenza subtype, thus necessitating frequent
updates of influenza vaccines to ensure optimal match
between the vaccine and prevailing influenza strains [8].
However, one modeling study suggests that loss of im-
munity to the same strain also represents an important
mechanism underlying the epidemiology of seasonal in-
fluenza [9]. One empirical study has shown a decline in
antibody titers, with only 52% of naturally infected and
34% of vaccinated individuals having hemagglutination
inhibition (HI) titers of ≥ 40 after 6 months of follow-up
[10]. However, another smaller study including both nat-
urally infected and vaccinated individuals reported a less
dramatic decrease, with only about 5% showing a 4-fold
or greater decline in antibody titers after ~1 year by both
HI and virus microneutralization (MN) assays [11].
Hence, greater clarity is required on the proportions of
individuals still having HI titers of ≥ 40 (which is often
considered as the threshold for a seroprotective response)
[12,13], as well as the rate of decline within the period
from 6 months to 1 year following seroconversion. In-
sights are also needed on whether the findings differ when
using HI and MN assays. In addition, several cohort stud-
ies have suggested that a substantial proportion of influ-
enza infections are asymptomatic [14-17], but it is unclear
if the immune responses in such infections are as robust
and durable as those observed in symptomatic influenza.
This study aimed to determine the possible waning of
post-infection antibodies by quantifying the rate of de-
cline in a cohort of individuals who seroconverted to A
(H1N1)pdm09, and were followed up at two additional
time-points, i.e. approximately 6 months and 1 year after
seroconversion. The study also estimated the proportions
with different antibody titers by both HI and MN assays,
and explored if there were differences by age, gender and
symptoms, as well as how estimates of seroconversion
may be affected by longer intervals between serological
samples in cohort studies of influenza infection.
Methods
Cohort study design and ethical review
Participants in this study were a subset of our previ-
ous cohort study, and comprised individuals aged 21 to
75 years from the multi-ethnic cohort of the Singapore
Consortium of Cohort Studies [14]. In our previous stu-
dy, each participant contributed a baseline pre-epidemic
sample (obtained between June 2005 to June 2009) and
up to two follow-up samples to determine whether they
seroconverted to A(H1N1)pdm09 from June to October
2009, when Singapore experienced the initial epidemic
of A(H1N1)pdm09 infections. All participants from
the original study who consented to continued parti-
cipation contributed additional blood samples between
April and September 2010, as well as answered a ques-
tionnaire survey administered concurrently [4]. We then
selected the subset of participants who seroconverted
(defined as a four-fold or greater increase in titers be-
tween any two successive samples by HI assays) to A
(H1N1)pdm09 between June and October 2009 to in-
vestigate subsequent antibody kinetics in later samples.
Participants who reported receipt of influenza vaccine
after October 2009 (which would have contained the
pandemic A/California/7/2009 strain) were excluded,
since this would have altered the subsequent trajectory
of antibody titers.
For each participant, we chose the blood sample with
the highest HI titer in 2009, which would have been
taken (between 20 to 29 August 2009) about 3 weeks
after incidence had peaked during the initial epidemic of
A(H1N1)pdm09 infections in Singapore, or (between
6 to 11 October 2009) when the epidemic had clearly
ended. This was used as a reference point (designated
as Sample A), both to detect seroconversion from pre-
epidemic samples, as well as to investigate how titers
changed over two subsequent samples collected in 2010,
as follows:
 Sample B collected from 8 to 22 April 2010, about 6
to 8 months after sample A.
 Sample C collected from 19 to 27 September 2010,
approximately 6 months after sample B (and more
than 12 to 14 months after sample A).
Finally, we also investigated how any decline in anti-
body titers might affect the proportion of serocon-
versions detected had we used longer intervals between
sampling time-points, by computing the number with
4-fold or greater rise in titers when independently com-
paring samples B and C against the pre-epidemic sam-
ple taken before the initial epidemic of infections which
started in mid-June 2009. The study was approved by the
Institutional Review Board of the National University of
Singapore.
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Influenza virus and serological assays
All samples (pre-epidemic and samples A to C) were
stored at −80°C before analyses by both HI and MN as-
says. HI assays for the pre-epidemic sample and sample
A were performed as a single batch of tests in November
2009 as part of our earlier study on the sero-incidence
of A(H1N1)pdm09 during the initial epidemic of infec-
tions in Singapore [14]. Samples B and C were batch-
tested by HI in December 2010 as part of our follow-up
study on subsequent epidemics of A(H1N1)pdm09 in
2010 [4]. The MN assays were conducted in November
2011, as an alternative means of verifying our observa-
tions on the marked changes in HI antibody titers found
in a preliminary analysis.
For the HI assay, sera from test participants were first
pre-treated with receptor-destroying enzyme (Denka
Seiken, Tokyo, Japan) at 1:4 (vol/vol) for 16 hours at
37°C, before enzyme inactivation by addition of an
equal volume of 1.6% trisodium citrate (Ajax Finechem,
Melbourne, Australia) and incubation for 30 minutes at
56°C. The HI assay was then performed according to
standard protocols at the World Health Organization Col-
laborating Center for Reference and Research on Influenza
in Melbourne, Australia [18]. Two-fold serial dilutions
were first performed on the treated serum in 96-well
V-bottom microtiter plates. The pandemic influenza
A/California/7/2009 virus was adjusted to 4 hemaggluti-
nation units per 25 μl (verified by back titration), and this
virus suspension was added to each of the 96 wells before
incubating for 30 minutes at room temperature. After this,
25 μl of freshly prepared 1.0% (vol/vol) turkey red blood
cells (RBCs) were added at room temperature, and the
plates were incubated for 30 minutes for the RBCs to set-
tle. Plates were read and HI titers were obtained from the
reciprocal of the highest serum dilution which contained
non-agglutinated RBCs. MN assays were performed at
the National University of Singapore using pandemic
influenza A/Singapore/GP2651/2009 virus isolated in
Singapore during the initial epidemic of A(H1N1)pdm09
infections, which has been used in MN work since the lat-
ter half of 2009 [19]. Basic Local Alignment Search Tool
(BLAST) analyses to compare the sequences of the
hemagglutinin and neuraminidase of the two A(H1N1)
pdm09 strains (i.e. A/California/7/2009 and A/Singapore/
GP2651/2009) revealed nucleotide and amino acid iden-
tities of 96-98%, thus confirming their strong homology.
Madin-Darby canine kidney (MDCK) cells were see-
ded with Eagle’s minimum essential medium or EMEM
(ATCC, Manassas, VA) in 96-well flat bottom plates and
incubated for 24 hours at 37°C with 5% CO2 to obtain
confluent monolayers. Two-fold serial dilutions of each
serum sample were performed using EMEM starting with
the 1:10 dilution. Equal volumes of 100 tissue culture in-
fective dose (TCID50) of A/Singapore/GP2651/2009 virus
(25 μl) and each serum dilution (25 μl) were incubated
for 2 hours at 35°C with 5% CO2. The cells were washed
thrice before adding serum-free medium containing
3 μg/ml of TPCK-treated trypsin (Sigma-Aldrich, St Louis,
MO), inoculated with the virus-serum mixtures, and then
incubated for 72 hours at 35°C with 5% CO2. The neutral-
izing antibody titer was defined as the reciprocal of the
highest serum dilution at which the infectivity of 100
TCID50 of virus for MDCK cells was completely neutra-
lized in 50% of the wells.
Statistical analyses
Geometric mean titers (GMTs) were estimated by assig-
ning a value of 5 for titers below 10, and a value of 1,280
for titers of 1,280 or higher. We then developed a multi-
nomial ordered probit model for the distribution of ti-
ters over three sampling periods to allow the rate of
change in the distribution of HI and MN titers to be es-
timated. This formulation permitted age, gender, symp-
toms as well as interactions with sampling periods, to be
adjusted for as potential confounders in the model. Indi-
viduals who had fever, sore throat, cough, nasal congestion
or shortness of breath were classified as symptomatic in-
fections, while those with none of these symptoms were
classified as asymptomatic infections. The likelihood of
the data was derived using the following model:





μij ¼ βTwij þ ∈ i
where xij is the jth observed titer for the ith partici-
pant, zij is a latent variable, a propensity for high titers,
and thresholds determining observations, μij controls the
location of the latent variable to ensure identifiability, wij
are individual-level covariates, ∈ i is a random effect term,
and θk are ordered thresholds. Markov chain Monte Carlo
sampler was developed to integrate over the space of un-
observed latent variables.
Given that our HI assays were performed in two bat-
ches and possible intra-laboratory variation of HI titers
between batches of replicate assays [20], we conducted a
simple sensitivity analysis. We repeated all our statistical
analyses based on the assumption that HI titers for sam-
ples B and C were up to 2-fold higher than what we
measured, and assessed if this would have changed any
of our main conclusions.
All statistical analyses were performed using the R sta-
tistical software 3.0.0 (Institute for Statistics and Mathe-
matics, Vienna, Austria).
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Results
Of the 838 participants originally enrolled, 727 had at
least one additional follow-up blood sample, of which 98
seroconverted to A(H1N1)pdm09. Of the 98 parti-
cipants, 70 also contributed samples B and C (in April
and September 2010). After excluding 3 participants who
reported receipt of influenza vaccine between October
2009 and September 2010, we were left with samples from
67 participants for analyses. Participants (30 males and 37
females) had a median age of 42.5 years (range 21 to
62 years), with 53 participants who reported symptoms.
Four participants had a 2-fold increase in HI titer, and an-
other 4 different participants had a 2-fold increase in MN
titer between successive assays. As a 2-fold change can be
considered to be within the margin of error for the re-
spective assays, these observations were retained in sub-
sequent analyses. However, one participant showed a
32-fold increase in HI and 16-fold increase in MN titers
between samples A and B, while another showed an 8-fold
increase in HI and 16-fold increase in MN titers between
samples B and C. Since these two participants may have
been re-infected, we excluded them from further analyses.
Figure 1 shows that titers from our HI and MN assays
for samples A to C were strongly and significantly corre-
lated (R-squared 0.45, P < 0.001), and that the degree of
correlation did not vary by sampling period. A HI titer
of 40 was approximately equivalent to a MN titer of 160,
the former being a commonly referenced correlate of
protection in immunological studies. We hence present
subsequent MN data with reference to a positive cut-off
titer of 160 and above.
Figure 2 presents the observed (bars) and modeled
(points) distribution of HI and MN titers from the
multinomial ordered probit regression over the 3 sam-
pling periods. It is noted that HI titers in particular are
not normally distributed. The chosen model provides a
reasonable fit to the data, with predicted 95% credible
intervals overlapping with the observed distribution in
almost all titer intervals. The model suggests that sam-
pling periods are significantly associated with a negative
change in titer by both HI and MN, as indicated by the
negative posterior means with 95% credible intervals
that are less than zero (Table 1). Female gender (by HI
assay) and presence of symptoms (by both HI and MN
assays) were also significantly associated with higher titer
distributions. There was significant interaction between
sampling period and age category, indicating that the
older age group (≥55 years) showed a significant de-
crease in excess of what would be expected for the youn-
ger age group for sampling period C by HI assay, and
both sampling periods B and C by MN assay. There was
also significant interaction between sampling period with
gender by the HI assay, and with symptomatic infections
by the MN assay. The effect of these interactions is illus-
trated in Figure 3, which models the mean HI and MN
titers with 95% credible intervals. While mean titers
were slightly higher in the older age group in sample A
by both HI and MN assays (Figures 3A and 3B respect-
ively), the rate of decrease was also faster, such that the
trajectory of the mean titers for the two age categories
crossed by sample B, and the mean and spread of titers
in sample C for those ≥ 55 years was lower than for
those aged < 55. We observed that women and symp-
tomatic infections had higher HI titers in sample A, but
a marginally faster rate of decline (Figures 3C and 3E),
so that titers were not substantially different by gender
or symptoms in samples B and C. By MN, the trajector-
ies of antibody decline for the two genders (Figure 3D)
were essentially parallel, and while there was a slightly
faster rate of decline from samples A to B, symptomatic
infections continued to show marginally higher titers in
samples B and C due to the substantially higher starting
titers in sample A.
Figures 4A and B illustrate the fraction which might
be below putative cut-off points for seroprotection, both
using our model and just the observed proportions. On
the observed data, 71% of all subjects had HI titers ≥ 40
and 72% had MN titers ≥ 160 in sample A, but the corre-
sponding proportions were only 25% and 40% by sample
B, and 14% and 37% by sample C. None of those aged ≥
55 years had HI titers ≥40 or MN titers ≥ 160 in sample
C, compared with 15% and 41% of those aged < 55 years
(P = 0.58 and P = 0.08 respectively). Results from the
modeled distribution were fairly similar, with confidence
intervals overlapping those from the observed data.
Figure 1 Scatterplot of titres from HI and MN assays. Random
jitter was added to separate overlapping data points, and different
coloured samples denote data from sample A (baseline) to sample
C. The straight line in black is for the best fitting regression model,
which has an R-squared of 0.51 (p<0.001).
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With HI assays, using longer time intervals between
sampling time-points substantially reduced the num-
ber of seroconversions detected. Only 27 and 23 par-
ticipants were found to seroconvert when comparing
the titers in samples B and C to the pre-epidemic
sample; i.e. only 42% and 35% of the 65 participants
who seroconverted by HI with sample A. Of these 65,
only 6 did not also seroconvert by MN assays be-
tween the pre-epidemic sample and sample A. Of the
59 who seroconverted, 56 (95%) were also assessed to
have seroconverted between the pre-epidemic sample and
sample B, and 53 (90%) between the pre-epidemic sample
and sample C.
In the sensitivity analysis, even assuming that HI titers
in samples B and C were up to 2-fold higher than what
we measured, we found that there would be significant
reduction in titers from samples A to B, and from A
to C (Additional file 1: Table S1). There were also no
changes to any of the factors and interaction terms
identified to be significant in the original regression
analysis, and we would still only observe seroconver-
sion in 37 (57%) and 34 (52%) of the 65 individuals
respectively when comparing titers of samples B and C
versus A (Additional file 1: Table S2).
Discussion
The objective of our study was to understand temporal
changes in antibody titers following seroconversion dur-
ing the initial epidemic of A(H1N1)pdm09 infections in
Singapore. Our results revealed a fairly rapid decline in
antibody titers following seroconversion, with only a fifth
of those who originally had HI titers of ≥ 40 and half of
those with MN titers of ≥ 160 still having titers above
the respective cut-off points after a year. There was also
some indication that the rate of decline was higher in
older individuals, and that the change in antibody titers
measured by HI was greater than by MN. Symptomatic
infections were associated with higher starting antibody
titers, and continued to have marginally higher titers in
subsequent samples, at least by MN assays.
Our cohort of participants who seroconverted between
June and October 2009, were presumptively infected for
the first time with A(H1N1)pdm09 during the initial
epidemic in Singapore which peaked in early August
2009 [21]. After its emergence, additional epidemics of A
(H1N1)pdm09 were observed in Singapore and elsewhere
[4,7], and mortality records suggests that similar phenom-
ena occurred in past pandemics [22]. Since lower antibody
titers do correlate with increased susceptibility [23], the
(See figure on previous page.)
Figure 2 Model goodness of fit of a multivariate ordered probit model to antibody titre distribution. In orange are HI assays (left column;
Figures 2A, 2C and 2E) and MN assays (right column; Figures 2B, 2D and 2F) at three time points in 2009 (Figures 2A and 2B), April 2010
(Figures 2C and 2D) and September 2010 (Figures 2E and 2F), with 95% confidence interval error bars. In black is the posterior predictive
distribution (mean and 95% credible interval). The ordered probit model accounts for age and sex as potential confounders, along with individual
random effects and a temporal decay in antibodies, and uses the same θ thresholds at all time points. All the non-Gaussian distribution, and
evolving shape of the distribution, are apparent, but the flexibility of the model formulation is able to account for both.
Table 1 Results of posterior means with 95% credible intervals of individual-level covariates estimated by the
multinomial ordered probit model
Factor By HI assay By MN assay
Posterior mean 95% credible interval Posterior mean 95% credible interval
Age≥ 55 years (versus age < 55 years) 1.06 (−1.12, 3.53) 1.21 (−1.18, 3.78)
Female (versus male) 1.37 (0.06, 2.71) 0.49 (−0.96, 1.98)
Any symptoms 2.07 (0.38, 3.84) 3.53 (1.60, 5.55)
Sample B (versus sample A) −2.96 (−4.24, −1.72) −0.90 (−1.95, 0.18)
Sample C (versus sample A) −3.54 (−4.96, −2.19) −2.31 (−3.49, −1.15)
Interaction terms
Age≥ 55 years with sample B −1.28 (−3.02, 0.40) −2.99 (−4.57, −1.46)
Age≥ 55 years with sample C −3.40 (−5.28, −1.57) −2.77 (−4.30, −1.26)
Female with sample B −1.44 (−2.37, −0.50) 0.66 (−0.19, 1.50)
Female with sample C −1.35 (−2.35, −0.37) 0.58 (−0.26, 1.46)
Any symptoms with sample B −0.66 (−1.89, 0.55) −1.63 (−2.77, −0.54)
Any symptoms with sample C −0.53 (−1.84, 0.79) −0.67 (−1.82, 0.47)
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Figure 3 Modelled antibody trajectories by age category and gender on HI and MN assays. In orange is the posterior predictive
distribution for individuals with age < 55 at three time points in 2009, April 2010 and September 2010, with 95% credible interval error bars
(3A, 3B). In black is the posterior predictive distribution for individuals with age ≥ 55, with 95% credible interval error bars (3A, 3B). In blue is the
posterior predictive distribution for males, with 95% credible interval error bars (3C, 3D). In pink is the posterior predictive distribution for women,
with 95% credible interval error bars (3C, 3D). In red is the posterior predictive distribution for patients with any respiratory symptoms, with 95%
credible interval error bars (3E, 3F). In grey is the posterior predictive distribution for patients without any respiratory symptoms, with 95%
credible interval error bars (3E, 3F).
Figure 4 Estimated and observed proportions by age and sampling period for titres above respective cut-off points for (A) HI ≥40, and
(B) MN ≥160. The orange bars with whiskers, which represent 95% confidence interval, indicate observed proportions stratifying by age
and sampling periods. The black points with 95% credible interval error bars represent the estimated proportions adjusting by age and
sampling periods.
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subsequent decline in antibody titers in this cohort offers
one possible explanation for re-infections, as well as for
recurrent epidemics of A(H1N1)pdm09 in Singapore be-
tween November 2009 to February 2010, and April to
June 2010 [4]. On the other hand, there have not been
large epidemics of A(H1N1)pdm09 in Singapore since
then (unpublished data), and the full picture may thus in-
volve a complex interaction of various factors beyond
what was observed in our study.
Our findings also have implications for the use of in-
fluenza vaccines. Other studies found that vaccination
against A(H1N1)pdm09 may induce a weaker response
than natural infection [11], and that HI titers decrease
significantly in both naturally infected and vaccinated
subjects after 6 months [10]. Our previous study on A
(H1N1)pdm09 infections confirmed by RT-PCR showed
that the proportion with HI titers of ≥ 40 remained rea-
sonably constant in samples collected up to 2 months
post-infection, but that a reduction in GMTs was just
about to become apparent by then [24]. In combination
with findings from this study, it would suggest the most
rapid decrease may be occurring between 2 to 6 months
after antibody titers peak, with a less marked decline in
the window between 6 months to 1 year. If antibody
decline in vaccinated subjects indeed follows what we
observed in natural infections, then influenza vaccine
should be given within 6 months of anticipated expos-
ure. While this is typically the case in temperate coun-
tries, the year-round risk of infection in the tropics [2]
makes this a much more challenging prospect, and may
require more frequent vaccination schedules. In addi-
tion, the faster rate of decline in the elderly may exacer-
bate the above issues with vaccination. Notwithstanding
the small number of elderly subjects in our study, the re-
sults are consistent with previous understanding on how
aging influences the magnitude and quality of the hu-
moral immune response by affecting both the size and
diversity of the B-cell repertoire and antibody affinity
[25]. A more rapid decline of specific immunity follow-
ing vaccination may also account for observations on
the questionable efficacy of influenza vaccine in older
compared to younger individuals [26,27], as well as shifts
in age distribution towards older individuals following a
pandemic, which we already observed in later epidemics
of A(H1N1)pdm09 infection in Singapore [6] and else-
where [7]. If indeed we are unable to maintain a durable
humoral immune response to influenza in the elderly,
then influenza vaccine development would need to focus
on alternative strategies such as stimulation of T-cell re-
sponses against influenza, as these may be better pre-
served than humoral immunity in the elderly [28-30]. In
addition, our findings also suggest that symptomatic in-
fections may generate more robust immune responses
than asymptomatic infections as indicated by the higher
titers observed in the former by both HI and MN. How-
ever, the data was less clear on whether such higher
titers would be sustained over time.
Furthermore, our results also have important impli-
cations for the conduct of future sero-epidemiological
studies, both using cross-sectional samples and cohort
studies. Spacing serum samples more than 6 months
apart may substantially underestimate infection rates by
seroconversion using HI, depending on the timing of in-
fections relative to the sample collection window, while
about 90% of the initial seroconversions by MN could
still be detected when using wider sampling intervals. If
using a cross-sectional approach to estimate infection
rates, we observed that, by samples B and C, only 25%
and 14% had HI titers of ≥ 40, which is also used as a
possible cut-off for indicating past infection. MN results
reflected relatively higher prevalence of neutralizing anti-
bodies, with 40% having titers ≥ 160 after 6 months and
37% after 1 year. More research is warranted to investi-
gate the reasons for the differential rate of decline by HI
and MN assays, and whether strain-specific antibody ti-
ters by HI or MN better predict protection against in-
fections with the same influenza strain. Some studies
comparing MN and HI to measure antibody responses
to influenza A(H1N1) have demonstrated greater sensi-
tivity of MN assays in the diagnosis of A(H1N1)pdm09,
e.g. 83% versus 71% [11,13], and this may be related to
differential antibody binding characteristics of the two
assays.
There were several limitations to our study. Firstly, for
logistical reasons, we opted to use different but antigeni-
cally homologous A(H1N1)pdm09 strains for our HI
and MN assays. Moreover, HI results were based on as-
says performed in the same laboratory but in two sepa-
rate batches. However, our sensitivity analysis indicated
that our conclusions would remain essentially the same
(unless titers in the second batch of HI assays were more
than 2-fold higher than what we measured). Notably,
while intra-laboratory variation of HI titers of up to 2-fold
in replicate assays is not uncommon, variation of more
than 2-fold is rare [20]. Another limitation was the rela-
tively small number of older subjects, and we must also
acknowledge that our cohort was based on presumptive
infections detected by seroconversion on HI assays. It
must be remembered that even amongst RT-PCR-positive
infections, about 20% do not seroconvert by HI, of which
a small proportion do seroconvert by MN [24]. Logistical
constraints prevented us from re-testing the entire set of
about 2,000 samples from the initial epidemic by MN
to identify these subjects. Secondly, we did not conduct
follow-up of our subjects to obtain virological samples,
and while we excluded 2 participants who were likely
re-infected (as indicated by a ≥ 4-fold rise in titer after
sample A), the remaining 65 participants could still
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have included some whose subsequent titers were boosted
by repeat exposure or infection. Had we been able to ex-
clude these individuals, we might have found the decrease
in titers to be even more dramatic. Finally, we must ac-
knowledge that while our study contributes some know-
ledge to the rate of decline in antibody titers following
initial seroconversion to A(H1N1)pdm09, we are unable
to address what might happen following repeated infec-
tions with the same strain, repeated infections with differ-
ent strains of the same subtype, as well as whether the
same findings apply to influenza A(H3N2) or influenza B.
Our cohort also comprised only healthy adults, and thus
we are unable to extrapolate our results to children or in-
dividuals with debilitating chronic illnesses.
Conclusions
Six months and one year after antibodies peaked follo-
wing presumptive infection with A(H1N1)pdm09, only
25% and 14% of participants respectively had antibody
titers against A(H1N1)pdm09 that would be considered
protective (HI titer ≥ 40). The decline in antibody titers
may explain susceptibility to re-infections, and recurrent
epidemics following the initial epidemic of infections
during the pandemic. It also suggests that influenza vac-
cination may have to be administered more frequently in
the tropics where there is year-round circulation of in-
fluenza viruses. The rate of decline in elderly individuals
may be even more rapid, and if our findings are con-
firmed, may necessitate alternative strategies of influenza
vaccine development for this vulnerable group.
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